The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Akifumi Takaori-Kondo sits on this spectrum.
This scientist: 498 publications — 95th percentile
95% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 1,028 publications or more.
The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Akifumi Takaori-Kondo sits on this spectrum.
This scientist: 68 D-Index — 61st percentile
61% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 167 D-Index or more.
Akifumi Takaori-Kondo is affiliated with Kyoto University in Japan and has contributed extensively to medical research, particularly in the fields of hematology and infectious diseases. Their work spans multiple subfields including molecular biology, oncology, and immunology, reflecting a broad research scope within the medical sciences.
The main topics of their research encompass acute myeloid leukemia, hematopoietic stem cell transplantation, and SARS-CoV-2 and COVID-19 research. Additional areas of focus include CAR-T cell therapy, immune cell function and interaction, multiple myeloma research and treatments, and lymphoma diagnosis and treatment.
Frequent publication venues for their work include Blood, International Journal of Hematology, bioRxiv (Cold Spring Harbor Laboratory), British Journal of Haematology, and Blood Advances. These venues indicate an emphasis on hematological and biomedical research environments.
Their frequently collaborating coauthors are Junya Kanda, Kotaro Shirakawa, Yasuyuki Arai, Tadakazu Kondo, and Toshio Heike, illustrating a collaborative research network within their field.
Significant recent papers authored or co-authored by Akifumi Takaori-Kondo include:
Their research contributions involve molecular mechanisms of viral infectivity, pathogenicity in SARS-CoV-2 variants, and clinical prognostic tools in myelodysplastic syndromes, among other topics.
Keisuke Kataoka;Yasunobu Nagata;Akira Kitanaka;Yuichi Shiraishi
Keisuke Kataoka;Yuichi Shiraishi;Yohei Takeda;Seiji Sakata
Akatsuki Saito;Takashi Irie;Rigel Suzuki;Tadashi Maemura;Tadashi Maemura
Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin
Lucy B. Cook;Shigeo Fuji;Olivier Hermine;Ali Bazarbachi
Shin Kawamata;Toshiyuki Hori;Akihiro Imura;Akifumi Takaori-Kondo
Keisuke Shindo;Akifumi Takaori-Kondo;Masayuki Kobayashi;Aierken Abudu
Masayuki Kobayashi;Akifumi Takaori-Kondo;Yasuhiro Miyauchi;Kazuhiro Iwai
Masatoshi Nishizawa;Kazuhisa Chonabayashi;Masaki Nomura;Azusa Tanaka
Sumie Fujii;Yasuo Miura;Aya Fujishiro;Takero Shindo
Yuichi Tanaka;Hiroyuki Marusawa;Hiroshi Seno;Yuko Matsumoto
Amane Sasada;Akifumi Takaori-Kondo;Kotaro Shirakawa;Masayuki Kobayashi
Shojiro Inano;Koichi Sato;Yoko Katsuki;Wataru Kobayashi
Ryo Yamamoto;Momoko Nishikori;Masaharu Tashima;Tomomi Sakai
Akihito Yonezawa;Rimpei Morita;Akifumi Takaori-Kondo;Norimitsu Kadowaki
Isabella Ferreira;Steven Kemp;Rawlings Datir;Akatsuki Saito
Keisuke Kataoka;Masako Iwanaga;Jun Ichirou Yasunaga;Yasunobu Nagata
Yasuyuki Arai;Yoko Nishinaka;Toshiyuki Arai;Makiko Morita
Yoko Nishinaka;Toshiyuki Arai;Souichi Adachi;Akifumi Takaori-Kondo
Keiya Uriu;Izumi Kimura;Kotaro Shirakawa;Akifumi Takaori-Kondo
If you think any of the details on this page are incorrect, let us know.
University of Alberta
Vrije Universiteit Amsterdam
University of Pittsburgh
University of Alabama
Kyoto University
Brigham and Women's Hospital
University of Salerno
University of Queensland
Amazon (United States)
City University of Hong Kong
Russian Academy of Sciences
University of Illinois at Chicago
Memorial Sloan Kettering Cancer Center
James Cook University
University of Montpellier
University of Edinburgh
